EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 32 / No 4 (Avril 2016) Med Sci (Paris), 32 4 (2016) 315-316 References
Free Access
Editorial
Issue
Med Sci (Paris)
Volume 32, Number 4, Avril 2016
Page(s) 315 - 316
Section Éditorial
DOI https://doi.org/10.1051/medsci/20163204001
Published online 02 May 2016
  1. Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst 1960 ; 25 : 85–109. [PubMed] [Google Scholar]
  2. Morange M. From the regulatory vision of cancer to the oncogene paradigm, 1975–1985. J Hist Biol 1997 ; 30 : 1–29. [CrossRef] [PubMed] [Google Scholar]
  3. Nowell PC. Genetic changes in cancer: cause or effect? Hum Pathol 1971 ; 2 : 347–348. [CrossRef] [PubMed] [Google Scholar]
  4. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000 ; 100 : 57–70. [CrossRef] [PubMed] [Google Scholar]
  5. Grünewald TGP, Gilardi-Hebenstreit P, Charnay P, Delattre O. Coopération entre mutation somatique et variant génétique de susceptibilité dans le sarcome d’Ewing. Med Sci (Paris) 2016 ; 32 : 323–326. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  6. Treps L, Gavard J. L’angiogenèse tumorale. Med Sci (Paris) 2015 ; 31 : 989–995. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  7. Solary E. Une approche réductionniste du cancer. Med Sci (Paris) 2014 ; 30 : 683–687. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  8. Deininger M. Hematology: curing CML with imatinib. A dream come true? Nat Rev Clin Oncol 2011 ; 8 : 127–128. [CrossRef] [Google Scholar]
  9. DeVita VT Jr, Eggermont AM, Hellman S, Kerr DJ. Clinical cancer research: the past, present and the future. Nat Rev Clin Oncol 2014 ; 11 : 663–669. [CrossRef] [Google Scholar]
  10. Ducasse H, Ujvari B, Solary E, et al. Can Peto’s paradox be used as the null hypothesis to identify the role of evolution in natural resistance to cancer? A critical review. BMC Cancer 2015 ; 15 : 792. [CrossRef] [Google Scholar]
  11. Tomasetti C, Vogelstein B. Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science 2015 ; 347 : 78–81. [CrossRef] [PubMed] [Google Scholar]
  12. Caulin AF, Graham TA, Wang LS, Maley CC. Solutions to Peto’s paradox revealed by mathematical modelling and cross-species cancer gene analysis. Philos Trans R Soc Lond B Biol Sci 2015 ; 370 : 1673. [CrossRef] [Google Scholar]
  13. Laplane L. Reprogramming and Stemness. Perspect Biol Med 2015 ; 58 : 229–246. [CrossRef] [PubMed] [Google Scholar]
  14. Bhat R, Bissell MJ. Of plasticity and specificity: dialectics of the microenvironment and macroenvironment and the organ phenotype. Wiley Interdiscipl Rev Dev Biol 2014 ; 3 : 147–163. [CrossRef] [Google Scholar]
  15. Cancer Versteeg R. Tumours outside the mutation box. Nature 2014 ; 506 : 438–439. [CrossRef] [PubMed] [Google Scholar]
  16. Merlevede J, Droin N, Qin T, et al. Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents. Nat Commun 2016 ; 7 : 10767. [CrossRef] [PubMed] [Google Scholar]
  17. Genovese G, Kähler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 2014 ; 371 : 2477–2487. [CrossRef] [PubMed] [Google Scholar]
  18. Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 2014 ; 371 : 2488–2498. [CrossRef] [PubMed] [Google Scholar]
  19. Martincorena I, Roshan A, Gerstung M, et al. Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science 2015 ; 348 : 880–886. [CrossRef] [PubMed] [Google Scholar]
  20. Le Jordan B. Graal de Grail est-il un mirage ? Med Sci (Paris) 2016 ; 32 : 417–420. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  21. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011 ; 144 : 646–674. [CrossRef] [PubMed] [Google Scholar]
  22. Hanoteau A, Henin C, Moser M. Chimiothérapie et immunothérapie, le même combat. Med Sci (Paris) 2016 ; 32 : 353–361. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  23. Ménager J, Gorin JB, Fichou N, et al. Radioimmunothérapie alpha : principes et intérêts en immunothérapie antitumorale. Med Sci (Paris) 2016 ; 32 : 362–369. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  24. Teillaud JL. Microenvironnements tumoraux : conflictuels et complémentaires. Med Sci (Paris) 2014 ; 30 : 343–462. [Google Scholar]
  25. Rutkowski MR, Svoronos N, Perales-Puchalt A, Conejo-Garcia JR. The tumor macroenvironment: cancer-promoting networks beyond tumor beds. Adv Cancer Res 2015 ; 128 : 235–262. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.